Anti-Angiogenic Effects of Synthesized Solid Lipid Nanoparticles Containing Foeniculum vulgare Essential Oil

Subject Areas : Journal of Animal Biology

Mohammad Sharifalhoseini ¹ , Ali Es-haghi ² , Gholamhasan Vaezi ³ , Hooman Shajiee ⁴

1 - Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
2 - Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran
3 - Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran
4 - Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran

Received: 2022-09-09 Accepted : 2022-09-15 Published : 2023-05-22

Keywords: Gene expression, angiogenesis, Solid lipid nanoparticles, Foeniculum vulgare Essential Oil,

Abstract :

Angiogenesis is a physiological process that involves the formation of new blood vessels, contributing to the development and progression of various diseases, including metastatic cancers, cardiovascular diseases, and inflammatory conditions. Vascular endothelial growth factor (VEGF) is one of the main regulators of tumor angiogenesis. Studies show that VEGF and its receptor (VEGF-R) are often upregulated in tumor tissues, and the overexpression of VEGF increases tumor growth and metastasis. This research aimedto synthesize solid-lipid nanoparticles containing Foeniculum vulgare essential oil and investigate its anti-angiogenic effects. For this purpose, the chick embryo chorioallantoic membrane (CAM) was used, and the expression of two important genes involved in the angiogenesis process, VEGF and VEGF-R was assessed using Real-Time PCR. The results showed a decrease in the growth rate of blood vessels in the CAM model, indicating the anti-angiogenic effects of the nanoparticles. Also, Real Time-PCR confirmed a decrease in the expression of the VEGF and VEGF-R genes. The results of this study showed that solid-lipid nanoparticles containing Foeniculum vulgare essential oil had anti-angiogenic properties and; therefore, can be useful agents for treating cancer.  

References:

1. Al-Abd A.M., Alamoudi A.J., Abdel-Naim A.B., Neamatallah T.A., Ashour O.M. 2017. Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies–a review. Journal of Advanced Research, 8: 591-605.


2. Banerjee I., De K., Mukherjee D., Dey G., Chattopadhyay S., Mukherjee M., Mandal M., Bandyopadhyay A.K., Gupta A., Ganguly S. 2016. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy. Acta Biomaterialia, 38: 69-81.


3. Battaglia L., Galliarate M., Peira E., Chirio D., Solazzi I., Giordano S.M.A., Gigiotti C.L., Riganti C., Dianzani C. 2015. Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology, 26: 255102.


4. Beedie S.L., Diamond A.J., Fraga L.R., Figg W.D., Vargesson N. 2017. Vertebrate embryos as tools for anti-angiogenic drug screening and function. Reproductive Toxicology, 70: 49-59.


5. Bergers G., Benjamin L.E. 2003. Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3: 401-410.


6. Bhattarai P., Hameed S., Dai Z. 2018. Recent advances in anti-angiogenic nanomedicines for cancer therapy. Nanoscale, 10: 5393-5423.


7. Cragg G.M., Pezzuto J.M. 2016. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Medical Principles and Practice, 25: 41-59.


8. Felmeden D., Blann A., Lip G. 2003. Angiogenesis: basic pathophysiology and implications for disease. European heart journal, 24: 586-603.


9. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. New england journal of medicine, 285: 1182-1186.


10. Fridlender M., Kapulnik Y., Koltai H. 2015. Plant derived substances with anti-cancer activity: from folklore to practice. Frontiers in Plant Science, 6: 799.


11. Gacche R.N., Meshram R.J. 2014. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1846: 161-179.


12. Gout S., Huot J. 2008. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenvironment, 1: 69-83.


13. Hua F., Shang S., Hu Z.W. 2017. Seeking new anti-cancer agents from autophagy-regulating natural products. Journal of Asian Natural Products Research, 19: 305-313.


14. Kajdaniuk D., Marek B., Borgiel-Marek H., Kos-Kudla B. 2011. Vascular endothelial growth factor (VEGF)-part 1: in physiology and pathophysiology. Endokrynologia Polska, 62: 444-455.


15. Kashyap D., Tuli H.S., Yeper M.B., Sharma A., Sak K., Srivastava S., Pandey A., Garg V. K., Sethi G., Bishayee A. Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Seminars in Cancer Biology, 2021: 5-23.


16. Mangir N.I., Dikici S., Clayessens F., Macneil S. 2019. Using ex ovo chick chorioallantoic membrane (CAM) assay to evaluate the biocompatibility and angiogenic response to biomaterials. ACS Biomaterials Science and Engineering, 5: 3190-3200.


17. Naik M., Brahma P., Dixit M. 2018. A cost-effective and efficient chick ex-ovo CAM assay protocol to assess angiogenesis. Methods and Protocols, 1: 19.


18. Naseri, N., Valizadeh H., Zakeri-Milani P. 2015. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Advanced Pharmaceutical Bulletin, 5: 305.


19. Papetti M., Herman I.M. 2002. Mechanisms of normal and tumor-derived angiogenesis. American Journal of Physiology-Cell Physiology, 282: C947-C970.


20. Rana S., Burke S.D., Karumanchi S.A. 2020. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. American Journal of Obstetrics and Gynecology, 226(2S):S1019-S1034.


21. Risau W. 1997. Mechanisms of Nature, 386: 671-674.


22. Roumi S., Tabrizi M.H., Eshaghi A., Abbasi N. 2021. Teucrium polium extract‐loaded solid lipid nanoparticles: A design and in vitro anticancer study. Journal of Food Biochemistry, 45: e13868.


23. Seca A.M.,Pinto C. 2018. Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application. International journal of molecular sciences, 19: 263.


24. Shibuya M. 2011. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes and Cancer, 2: 1097-1105.


25. Vasan N., Baselga J., Hyman D.M. 2019. A view on drug resistance in cancer. Nature, 575: 299-309.


26. Wyld L., Audisio R.A., Poston J. 2015. The evolution of cancer surgery and future perspectives. Nature reviews Clinical oncology, 12: 115-124.


27. Yadav L., Puri N., Rastogi V., Satpute P., Sharma V. 2015. Tumour angiogenesis and angiogenic inhibitors: a review. Journal of Clinical and Diagnostic Research,, 9: XE01.


28. Yadollahi R., Vasilev K., Simovic S. 2015. Nanosuspension technologies for delivery of poorly soluble drugs. Journal of Nanomaterials, 16375:1-13.